Europe — EMA
Osvyrti Accord Healthcare (Denosumab)
Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a monoclonal antibody presented as a injection for subcutaneous use.
Request sourcing
What is Denosumab?
Denosumab, the active ingredient in Osvyrti Accord Healthcare, is a monoclonal antibody presented as a injection for subcutaneous use. It treats osteoporosis and bone loss conditions in postmenopausal women and men at high risk of fractures. GNH USA supplies Osvyrti Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
GNH USA supplies Osvyrti Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Denosumab used for?
Denosumab is a R‑ ....
- Osteoporosis: ...
What are the side effects of Denosumab?
Common ...
What precautions apply to Denosumab?
Prec...
What does Denosumab interact with?
....
